The ASCO Post

New findings from the phase III ASCENT-04 trial may help redefine first-line treatment for PD-L1–positive metastatic triple-negative breast cancer.

Sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival 2 (PFS2) compared with chemotherapy plus pembrolizumab, providing further evidence for the potential of antibody-drug conjugate and immunotherapy combinations.

Presented by Kevin Kalinsky, MD, MS, FASCO, of Winship Cancer Institute of Emory University at

https://ascopost.com/news/june-2026/sacituzumab-govitecan-with-pembrolizumab-extends-pfs2-in-pd-l1-positive-metastatic-triple-negative-breast-cancer/

As generative AI becomes more accessible, patients and caregivers are increasingly turning to these tools for cancer-related information.

In this discussion, Rashad Ismayilov, MD, of Baskent University, and Ravi Parikh, MD, MPP, FACP, of Emory University and the Editor-in-Chief of ASCO AI in Oncology, review findings on how patients and caregivers are using generative AI tools, offering valuable insights into adoption patterns, trust, and experiences of patients with cancer and caregivers seeking cancer information.

Understanding how patients engage with AI may be just as important as clinicians understanding the technology.

https://ascoai.org/videos/newsreels/2026/patient-and-caregiver-usage-of-generative-ai-tools-for-cancer-information-in-turkey/

Advances in aggressive B-cell lymphomas continue to build on the foundation of R-CHOP.

New research suggests that combining targeted immunotherapies with standard R-CHOP may significantly delay disease progression, offering a promising strategy to improve outcomes in patients with aggressive lymphoma.

A strong development in the evolving treatment landscape for B-cell malignancies.

Presented by Georg Lenz, MD, of University Hospital Münster at

https://ascopost.com/news/june-2026/combining-targeted-immunotherapies-with-standard-r-chop-delays-progression-of-aggressive-b-cell-lymphomas/